LAS VEGAS, Feb. 6 /PRNewswire-FirstCall/ -- Las Vegas-based MediCor Ltd. (OTC:MDCR) (BULLETIN BOARD: MDCR) , the world's third largest manufacturer and distributor of breast implants, today announced results for its second fiscal quarter ending December 31, 2005. Sales for the three months ending December 31, 2005, were $6,981,294, an increase of $836,040, or 14%, when compared to the prior-year quarter. Excluding the effect of the decline in the euro relative to the dollar, sales increased 17%. Net loss for the quarter decreased to $4,141,712 from $4,306,139 in the comparable period in 2004. Basic and diluted loss per share for the quarter ending December 31, 2005, was $(0.21) compared to $(0.26) for the quarter ending December 31, 2004. Sales for the six months ended December 31, 2005, were $12,643,309, an increase of $354,996, or 3%, when compared to the same period of the prior year. Excluding the effect of the decline in the euro relative to the dollar, sales increased 5%. Net loss for the six-month period increased to $8,243,133 from $7,632,003 in the comparable period in 2004. Basic and diluted loss per share for the six-month period ending December 31, 2005, was $(0.42) compared to $(0.46) for the six months ending December 31, 2004. Theodore R. Maloney, MediCor's Chief Executive Officer stated, "We are very pleased that our second quarter sales returned to double-digit growth in the face of price competition from other manufacturers. Our planned acquisition of Biosil Limited and Nagor Limited, the United Kingdom-based manufacturer and supplier of saline-filled and silicone-filled breast implants, remains on track for completion during the first half of this year. These acquisitions will further strengthen our position in the global breast implant market and provide us with a larger platform from which to expand our business internationally. It also will help us respond more effectively to the aggressive pricing tactics of our competitors, such as what we saw in this last quarter." "We are also moving forward with our longer term plans to address the U.S. market place," Maloney said, "Our investment in clinical trials for our saline-filled breast implants continues, and during the quarter we also advanced our plans to file for an investigational device exemption as a first step toward U.S. approval for our high-consistency silicone-filled breast implants." Added David Barella, Executive Vice President of International Marketing and Sales, "During the second fiscal quarter, we successfully expanded our market share in a competitive pricing environment that has eased somewhat, but remains a challenge. Our creative new marketing programs for both surgeons and prospective patients are specifically designed to add significant value to our products, as well as to differentiate us from the competition. We are confident that these and other innovative strategies will help us continue to increase volumes and ultimately establish optimal price points for our products. In the coming year, we believe these strategies will have ideally positioned us to build on the strong 8% sales growth we have experienced in the last four quarters." About MediCor Ltd. MediCor was founded by Chairman of the Board Donald K. McGhan, the pioneer of the modern day breast implant industry. The Company acquires, develops, manufactures and markets products for medical specialties in aesthetic, plastic and reconstructive surgery and dermatology markets. Products include surgically implantable prostheses for aesthetic, plastic and reconstructive surgery and scar management products. Its products are sold worldwide to hospitals, surgery centers and physicians through various distributors and direct sales personnel. MediCor's strategy is to be the leading integrator of selected international medical device markets, technologies and corporations. To achieve this strategy, MediCor intends to build upon and expand its business lines, primarily in the aesthetic, plastic and reconstructive surgery and dermatology markets. MediCor intends to accomplish this growth through the expansion of existing product lines and offerings and through the acquisition of companies and other assets, including intellectual property rights or distribution rights. Forward-Looking Statements This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of MediCor's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the ability to obtain requisite financing for acquisitions to continue to execute on our growth plans, the risk of instability in the capital markets in the U.S. and internationally, the ability to obtain governmental approvals to market the company's products and the timing of the company's and its competitors' approvals and entry to markets needed to operate our businesses; the risk that businesses we acquire will not be integrated successfully; the risk that cost savings from acquisition transactions may not be realized or may take longer to realize than expected; disruption from transactions making it more difficult to maintain relationships with customers, employees or suppliers; increased competition and its effect on pricing, spending, third-party relationships and revenues; the outcome of legal proceedings; the risk of new and changing regulations in the U.S. and internationally. Additional factors that could cause MediCor's results to differ materially from those described in the forward-looking statements can be found in MediCor's Annual Report on Form 10-KSB for the year ended June 30, 2005, which was filed with the Securities and Exchange Commission and is available at the Securities and Exchange Commission's Internet site (http://www.sec.gov/). DATASOURCE: MediCor Ltd. CONTACT: Marc S. Sperberg, U.S., +1-702-932-4560, x308; or Mark Collinson, of CCG Investor Relations, U.S., +1-310-231-8600, x117, both for MediCor Ltd. Web site: http://medicorltd.com/

Copyright